Abstract
Current diagnostic methods in prostate cancer are lacking in their ability to predict individual patient outcome which highlights the need for more sensitive prognostic markers. Biological markers are seen as attractive and relevant candidates in current efforts to improve prognostic methods. Since metastasis is the most important component of cancer progression and mortality, markers which are able to predict the likely acquisition of the metastatic phenotype, before the onset of metastases, would be extremely useful clinically. This review outlines various metastasis suppressor genes and metastasis promoters which might have potential prognostic use in prostate cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lijovic, M., Fabiani, M., Bader, J. et al. Prostate cancer: are new prognostic markers on the horizon?. Prostate Cancer Prostatic Dis 3, 62–65 (2000). https://doi.org/10.1038/sj.pcan.4500408
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500408
- Springer Nature Limited
Keywords
This article is cited by
-
Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer
BMC Urology (2008)
-
Quantitative expression profile of PSGR in prostate cancer
Prostate Cancer and Prostatic Diseases (2006)